The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Open accessAbstract
PURPOSE: Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [(68)Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. [(18)F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare [(68)Ga]Ga-PSMA-HBED-CC and [(18)F]DCFPyL for clinical use in biochemically relapsed prostate cancer. PROCEDURES: In 14 selected patients with PSA relapse of prostate cancer, [(18)F]DCFPyL PET/X-ray computed tomography (CT) was performed in addition to [(68)Ga]Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value (SUV)max and the lesion to background ratios. RESULTS: All suspicious lesions identified by [(68)Ga]Ga-PSMA-HBED-CC were also detected with [(18)F]DCFPyL. In three patients, additional lesions were observed using [(18)F]DCFPyL PET/CT. The mean SUVmax in the concordant [(18)F]DCFPyL PSMA-positive lesions was significantly higher as compared to [(68)Ga]Ga-PSMA-HBED-CC (14.5 vs. 12.2, p = 0.028, n = 15). The mean tumor to background ratios (n = 15) were significantly higher for [(18)F]DCFPyL compared to [(68)Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs (p = 0.006, p = 0.002, p = 0.008), but no significant differences were found using the liver (p = 0.167) or the mediastinum (p = 0.363) as reference organs. CONCLUSION: [(18)F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [(18)F]DCFPyL represents a highly promising alternative to [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1997) · PubMed · Cited by 1,541
Afshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Afshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 921
Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Hadaschik, B. A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 915
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W.-E., Wängler, C., Mier, W., Haberkorn, U., & Eisenhut, M. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200279b · Cited by 843
Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Szabo, Z., Mena, E., Rowe, S. P., Plyku, D., Nidal, R., Eisenberger, M. A., Antonarakis, E. S., Fan, H., Dannals, R. F., Chen, Y., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0850-8 · Cited by 443
Chen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., & Pomper, M. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1357 · Cited by 388
Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Mehes, G. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 384
Cited by
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 958
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Pienta, K. J., Gorin, M. A., Rowe, S. P., Carroll, P. R., Pouliot, F., Probst, S., Saperstein, L., Preston, M. A., Alva, A. S., Patnaik, A., et al. (2021) · Journal of Urology · doi:10.1097/ju.0000000000001698 · Cited by 398
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D., Wong, J. Y. C., Pantel, A. R., Cho, S. Y., Gage, K. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4573 · Cited by 389
Metadata
- Authors
- Dietlein, M., Kobe, C., Kuhnert, G., Stockter, S., Fischer, T., Schomäcker, K., Schmidt, M., Dietlein, F., Zlatopolskiy, B. D., Krapf, P., Richarz, R., Neubauer, S., Drzezga, A., & Neumaier, B.
- Venue
- Molecular Imaging and Biology
- Published
- 2015-05-27
- Volume
- 17
- Issue
- 4
- Pages
- 575-584
- ISSN
- 1536-1632 (ISSN-L)
- 1860-2002
- OpenAlex
- W1517749817
- Cited by
- 355
- References
- 17
- FWCI
- 33.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. https://app.cochat.ai/papers/10.1007/s11307-015-0866-0
- The paper
- Dietlein, M., Kobe, C., Kuhnert, G., Stockter, S., Fischer, T., Schomäcker, K., Schmidt, M., Dietlein, F., Zlatopolskiy, B. D., Krapf, P., Richarz, R., Neubauer, S., Drzezga, A., & Neumaier, B. (2015). Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Molecular Imaging and Biology. https://doi.org/10.1007/s11307-015-0866-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.